A combination of 5-fluorouracil and membrane-bound antibody inhibits B-cell lymphoma growth in a mouse model system [1]

Leukemia and Lymphoma

Volumn 48, Issue 2, 2007, Pages 406-409

  Bonsignori, Mattia ^a,c,d   D'Costa, Sybil ^a,e   Surman, Sherri ^a   Hurwitz, Julia ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e BECKMAN COULTER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; FLUOROURACIL; ANTINEOPLASTIC ANTIMETABOLITE; CD40 ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; CANCER INHIBITION; CELL COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; DRUG EFFICACY; DRUG POTENTIATION; LETTER; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHORT COURSE THERAPY; TREATMENT RESPONSE; ANIMAL; CELL CULTURE; CELL MEMBRANE; DISEASE MODEL; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SURVIVAL RATE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; ANTIMETABOLITES, ANTINEOPLASTIC; CELL MEMBRANE; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; FLUOROURACIL; LYMPHOMA, B-CELL; MICE; MICE, SCID; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 34247882959     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601078738     Document Type: Letter

References (15)

1. Pui, C. H. and Evans, W. E. (1998) Acute lymphoblastic leukemia. N Eng J Med, 339, pp. 605-615.
2. Levi, F., Lucchini, F., Negri, E., Barbui, T. and La Vecchia, C. (2000) Trends in mortality from leukemia in subsequent age groups. Leukemia, 14, pp. 1980-1985.
3. Szocinski, J. L., Khaled, A. R., Hixon, J., Halverson, D., Funakoshi, S. and Fanslow, W. C. (2002) Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: Induction of bax. Blood, 100, pp. 217-223.
4. Schattner, E. J., Elkon, K. B., Yoo, D. H., Tumang, J., Krammer, P. H. and Crow, M. K. (1995) CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med, 182, pp. 1557-1565.
5. Kelley, S. K., Gelzleichter, T., Xie, D., Lee, W. P., Darbonne, W. C. and Qureshi, F. (2006) Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol, 148, pp. 1116-1123.
6. Law, C. L., Gordon, K. A., Collier, J., Klussman, K., McEarchern, J. A. and Cerveny, C. G. (2005) Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res, 65, pp. 8331-8338.
7. Longley, D. B., Harkin, D. P. and Johnston, P. G. (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer, 3, pp. 330-338.
8. D'Costa, S. and Hurwitz, J. L. (2003) Customized mitogen or antibody treatments enhance the sensitivity of lymphoid tumors to 5-fluorouracil in vitro and in vivo. Leuk Lymphoma, 44, pp. 841-847.
9. Hill, S. C., Youde, S. J., Man, S., Teale, G. R., Baxendale, A. J. and Hislop, A. (2005) Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol, 174, pp. 41-50.
10. Ghia, P., Boussiotis, V. A., Schultze, J. L., Cardoso, A. A., Dorfman, D. M. and Gribben, J. G. (1998) Unbalanced expression of bcl-2 family proteins in follicular lymphoma: Contribution of CD40 signaling in promoting survival. Blood, 91, pp. 244-251.
11. D'Costa, S. S. and Hurwitz, J. L. (2003) Phytohemagglutinin inhibits lymphoid tumor growth in vitro and in vivo. Leuk Lymphoma, 44, pp. 1785-1791.
12. Kotzin, B. L., Leung, D. Y., Kappler, J. and Marrack, P. (1993) Superantigens and their potential role in human disease. Adv Immunol, 54, pp. 99-166.
13. Suffredini, A. F., Fromm, R. E., Parker, M. M., Brenner, M., Kovacs, J. A. and Wesley, R. A. (1989) The cardiovascular response of normal humans to the administration of endotoxin. N Eng J Med, 321, pp. 280-287.
14. Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L. and Tubiana-Hulin, M. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol, 23, pp. 4265-4274.
15. Spina, M. and Tirelli, U. (2005) Rituximab for HIV-associated lymphoma: weighing the benefits and risks. Curr Opin Oncol, 17, pp. 462-465.